Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeras (PROTACs) comprising of E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton tyrosine kinase (BTK) binding moiety through a linker. They are reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.